Biocryst Pharmaceuticals Awarded Contract by the National Institute of Allergy And Infectious Diseases (NIAID) to Develop BCX4430 for the Treatment of Marburg Virus Disease

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has contracted with BioCryst for the development of BCX4430 as a treatment for Marburg virus disease. NIAID, part of the National Institutes of Health, has made an initial award of $5.0 million to BioCryst. The total funding could be up to $22.0 million over five years, if all contract options are exercised. BCX4430 is the lead compound in BioCryst’s broad-spectrum antiviral (BSAV) research program.

Help employers find you! Check out all the jobs and post your resume.